Top Key Companies for Pharmaceutical CMO and CDMO Market: Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL.
Global Pharmaceutical CMO and CDMO Market Size was estimated at USD 16473.68 million in 2022 and is projected to reach USD 18023.69 million by 2028, exhibiting a CAGR of 1.51% during the forecast period.
Global Pharmaceutical CMO and CDMO Market Overview And Scope:
The Global Pharmaceutical CMO and CDMO Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Pharmaceutical CMO and CDMO utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Pharmaceutical CMO and CDMO Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical CMO and CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pharmaceutical CMO and CDMO market.
Global Pharmaceutical CMO and CDMO Market Segmentation
By Type, Pharmaceutical CMO and CDMO market has been segmented into:
API CMO and CDMO
FDF CMO and CDMO
Packaging CMO
Clinical CDMO
By Application, Pharmaceutical CMO and CDMO market has been segmented into:
Pharmaceutical Company
Biotechnology Company
Other
Regional Analysis of Pharmaceutical CMO and CDMO Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Pharmaceutical CMO and CDMO Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Pharmaceutical CMO and CDMO market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Pharmaceutical CMO and CDMO market.
Top Key Companies Covered in Pharmaceutical CMO and CDMO market are:
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Pharmaceutical CMO and CDMO Market by Type
5.1 Pharmaceutical CMO and CDMO Market Overview Snapshot and Growth Engine
5.2 Pharmaceutical CMO and CDMO Market Overview
5.3 API CMO and CDMO
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 API CMO and CDMO: Geographic Segmentation
5.4 FDF CMO and CDMO
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 FDF CMO and CDMO: Geographic Segmentation
5.5 Packaging CMO
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Packaging CMO: Geographic Segmentation
5.6 Clinical CDMO
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Clinical CDMO: Geographic Segmentation
Chapter 6: Pharmaceutical CMO and CDMO Market by Application
6.1 Pharmaceutical CMO and CDMO Market Overview Snapshot and Growth Engine
6.2 Pharmaceutical CMO and CDMO Market Overview
6.3 Pharmaceutical Company
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Pharmaceutical Company: Geographic Segmentation
6.4 Biotechnology Company
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Biotechnology Company: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Pharmaceutical CMO and CDMO Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Pharmaceutical CMO and CDMO Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Pharmaceutical CMO and CDMO Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 LONZA
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CATALENT
7.4 THERMO FISHER SCIENTIFIC
7.5 SAMSUNG BIOLOGICS
7.6 FAREVA
7.7 WUXI APPTECH
7.8 WUXI BIOLOGICS
7.9 SIEGFRIED
7.10 FUJIFILM DIOSYNTH BIOTECHNOLOGIES
7.11 ASYMCHEM
7.12 PFIZER CENTREONE
7.13 DELPHARM
7.14 RECIPHARM
7.15 AGC PHARMA CHEMICALS
7.16 BOEHRINGER INGELHEIM
7.17 VETTER
7.18 CURIA
7.19 AENOVA
7.20 PORTON
7.21 PIRAMAL
7.22 STRIDES PHARMA
7.23 NEXTPHARMA
7.24 FAMAR
7.25 JUBILANT
7.26 ALCAMI
7.27 EUROAPI
7.28 EUROFINS
7.29 AVID BIOSERVICES
7.30 BIOVECTRA
7.31 CPL
Chapter 8: Global Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 API CMO and CDMO
8.2.2 FDF CMO and CDMO
8.2.3 Packaging CMO
8.2.4 Clinical CDMO
8.3 Historic and Forecasted Market Size By Application
8.3.1 Pharmaceutical Company
8.3.2 Biotechnology Company
8.3.3 Other
Chapter 9: North America Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 API CMO and CDMO
9.4.2 FDF CMO and CDMO
9.4.3 Packaging CMO
9.4.4 Clinical CDMO
9.5 Historic and Forecasted Market Size By Application
9.5.1 Pharmaceutical Company
9.5.2 Biotechnology Company
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 API CMO and CDMO
10.4.2 FDF CMO and CDMO
10.4.3 Packaging CMO
10.4.4 Clinical CDMO
10.5 Historic and Forecasted Market Size By Application
10.5.1 Pharmaceutical Company
10.5.2 Biotechnology Company
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 API CMO and CDMO
11.4.2 FDF CMO and CDMO
11.4.3 Packaging CMO
11.4.4 Clinical CDMO
11.5 Historic and Forecasted Market Size By Application
11.5.1 Pharmaceutical Company
11.5.2 Biotechnology Company
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 API CMO and CDMO
12.4.2 FDF CMO and CDMO
12.4.3 Packaging CMO
12.4.4 Clinical CDMO
12.5 Historic and Forecasted Market Size By Application
12.5.1 Pharmaceutical Company
12.5.2 Biotechnology Company
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 API CMO and CDMO
13.4.2 FDF CMO and CDMO
13.4.3 Packaging CMO
13.4.4 Clinical CDMO
13.5 Historic and Forecasted Market Size By Application
13.5.1 Pharmaceutical Company
13.5.2 Biotechnology Company
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Pharmaceutical CMO and CDMO Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 API CMO and CDMO
14.4.2 FDF CMO and CDMO
14.4.3 Packaging CMO
14.4.4 Clinical CDMO
14.5 Historic and Forecasted Market Size By Application
14.5.1 Pharmaceutical Company
14.5.2 Biotechnology Company
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Pharmaceutical CMO and CDMO Scope:
|
Report Data
|
Pharmaceutical CMO and CDMO Market
|
|
Pharmaceutical CMO and CDMO Market Size in 2025
|
USD XX million
|
|
Pharmaceutical CMO and CDMO CAGR 2025 - 2032
|
XX%
|
|
Pharmaceutical CMO and CDMO Base Year
|
2024
|
|
Pharmaceutical CMO and CDMO Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL.
|
|
Key Segments
|
By Type
API CMO and CDMO
FDF CMO and CDMO
Packaging CMO
Clinical CDMO
By Applications
Pharmaceutical Company
Biotechnology Company
Other
|
